In 2017, the IVD market in China was estimated at $3,200 million and is expected to show annual growth of 13.2% to reach $5,955 million in 2022. Supporting growth will be a modernizing healthcare infrastructure and steady migration from manual to automated processes.
As an in vitro diagnostics (IVD) market, China trails only the populous, developed economy markets of the United States, western European countries, and Japan. The country and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, and diseases of aging.
This report provides the following market data:
- Market by Province (Guangdong, Shangdong, Henan, Sichuan, Jiangsu, Hebei, Hunan, Anhui, Zhejiang, Others)
- Market by Rural/Urban
- Regulatory Process for IVD Products in China
- Companies Operating in China
- Disease Statistics in China
- Healthcare Spending in China
- Economic Statistics
- Market Drivers and Restrainers
- Venues for IVD Test Usage
The report is designed to provide the reader with an overview of the Chinese laboratory market and its influences. The focus is on the IVD discipline including reagents, consumables, calibrators and controls of the following sub-segments:
Clinical Chemistry: routine lab testing; substrates, enzymes, homogeneous immunoassays, proteins, ISE (non-POC), HBA1c (non-POC), includes urinalysis and blood chemistry testing.
Immunoassays: hormones and thyroid function, tumor markers, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT, toxicology and common infectious diseases (HIV, hepatitis, influenza)
Microbiology and Molecular Testing: manual and automated tests, culture media (to be prepared or ready to use), latex tests, transport media, blood culture, sensitivity discs, Gram and other stains, MTB culture, Mycoplasma, Ureaplasma, nucleic acid testing.
Point-of-Care Testing: all POC tests for cardiology, toxicology, coagulation, diabetes, infectious diseases, including POC and non-POC blood gas and electrolytes, and glucose self-monitoring tests.
Histology/Cytology: PAP, HE, IHC, ISH, FISH, primary and secondary antibodies.
Included in the report are trends influencing the industry and country-level data including incidence of disease, life expectancy, population demographics, economic status, healthcare utilization and other market influences.
Key Topics Covered
1. Executive Summary
2. China in Context
3. Clinical Laboratory Structure in China
4. IVD Markets in China
5. Company Activity in China
- China IVD Market Participant Overview
- Abbott Laboratories
- Becton, Dickinson & Co.
- bioMerieux, Inc.
- Bio-RAD Laboratories, Inc.
- Danaher Corp.
- Hologic, Inc.
- Horiba Medical
- Instrumentation Laboratory
- Laboratory Corporation of America
- Luminex Corporation
- Mindray Medical International, Ltd.
- Myriad Genetics
- Ortho Clinical Diagnostics
- Promega Corporation
- Qiagen N.V.
- Shanghai Kehua Bio-engineering
- Siemens AG
- Sysmex Corp.
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/bqbn6j/ivd_market_in?w=4